- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04955015
Associations of Carotid Plaque Characteristics With Brain Perfusion and Cognitive Function in Patients Undergoing CEA
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Cerebrovascular disease is the first cause of death and adult disability in China. More than 75% of the patients in China have ischemic cerebrovascular disease, and about 33.3% of them have ipsilateral extracranial carotid stenosis. One of the main causes of carotid stenosis is atherosclerosis. Atherosclerotic plaques can be divided into two types: stable plaques and vulnerable plaques. Vulnerable plaque has the tendency to rupture, prone to thrombosis and rapid progression of dangerous plaque. Its pathological characteristics are mainly as follows: thin fibrous cap (or fibrous cap has been broken), large lipid nucleus, massive hemorrhage in plaque, rich in inflammatory cells, abundant neovascularization and plaque surface calcification. Vulnerable plaque is the main cause of stroke. At present, high-resolution magnetic resonance imaging combined with multi sequence is one of the best methods to evaluate carotid artery stenosis, which is helpful to analyze plaque characteristics.
At present, the main treatment methods of carotid artery stenosis are: carotid endarterectomy (CEA) and carotid angioplasty with stenting (CAS). Large scale multicenter prospective randomized trials and meta-analysis have established CEA as the gold standard for the treatment of carotid arerosclerotic stenosis.
Studies have shown that the ipsilateral cerebral perfusion is continuously decreased due to carotid artery stenosis, and CEA operation can relieve the vascular stenosis and improve the cerebral perfusion. However, the relationship between cerebral perfusion improvement after CEA and the quantitative characteristics of vulnerable plaque is still lack of sufficient evidence. Vascular cognitive impairment is closely related to the progress of carotid stenosis. The main mechanisms are microemboli formation, white matter injury and central nervous function decline caused by long-term chronic hypoperfusion. The formation and continuous hypoperfusion of microemboli further increase the burden of white matter disease. Studies have shown that the visual spatial executive ability, naming ability, attention ability and abstract profile ability of patients after CEA are significantly improved. However, there is still insufficient evidence about the relationship between the MRI features of vulnerable carotid plaques and the improvement of cognitive function after CEA.
We hope to achieve the following goals: 1) to explore the associations between carotid vulnerable plaque characteristics and cerebral perfusion in patients undergoing CEA; 2) to explore the associations between the characteristics of vulnerable carotid plaques and cognitive function in patients undergoing CEA.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Ran Huo, Dr.
- Telefonnummer: 010-82264374
- E-post: ransmile216@163.com
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Peking University Third Hospital
-
Ta kontakt med:
- Huishu Yuan, Dr.
- Telefonnummer: 010-82264188
- E-post: huishuy@bjmu.edu.cn
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Over 30 years old;
- The patients with symptomatic (>50%) or asymptomatic carotid stenosis (> 70%) measured by computed tomography angiography (CTA) or B-mode ultrasonography
- CEA operation will be performed in our hospital.
Exclusion Criteria:
- The history of CEA operation in the last 3 months;
- Diseases (AF, valve diseases, etc.) that may cause cardiac thrombosis;
- Contraindications of MR examination (vascular stent implantation, pacemaker, metal or magnetic plants in vivo, claustrophobia, etc.) were found;
- Contraindications of contrast agents: such as renal failure, iodine or gadolinium contrast agent allergy;
- Having heart or respiratory failure;
- Serious consciousness disorder (coma, etc.);
- Brain tumor;
- Acute cerebral hemorrhage;
- Pregnant women or planned pregnancies in the past 2 years;
- Who does not agree to sign the informed consent.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
patients
patients with caotid atherosclerosis refering to carotid endarterectomy
|
patients with carotid atherosclerosis refering to CEA
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
brain perfusion
Tidsramme: From preoperative to 24 months after operation (CEA)
|
perioperative brain perfusion and changes of brain perfusion in patients underging CEA
|
From preoperative to 24 months after operation (CEA)
|
cognitive function
Tidsramme: From preoperative to 24 months after operation (CEA)
|
perioperative cognitive function and cognitive changes in patients underging CEA
|
From preoperative to 24 months after operation (CEA)
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- M2019292
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Carotis endarterektomi
-
AstraZenecaFullførtCarotid Intima- MedietykkelseIndia
-
Hospices Civils de LyonHar ikke rekruttert ennåCAROTID STENOSISFrankrike
-
Boston Scientific CorporationFullførtVasovagal synkope | Arytmi | Atrioventrikulær hjerteblokk | Kronisk Bundle Branch eller Branch Block | Carotid sinus overfølsomhetsreaksjonssyndromKina
Kliniske studier på carotid endarterectomy
-
Meshalkin Research Institute of Pathology of CirculationFullførtPasienter med aterosklerotisk carotisstenose | Symptomatiske pasienter (stenose > 50 %) | Asymptomatiske pasienter (stenose ≥80 %)Den russiske føderasjonen
-
Boston Scientific CorporationMassachusetts General Hospital; Beth Israel Deaconess Medical Center; CRO... og andre samarbeidspartnereFullførtSlag | Carotis stenose | CarotisarteriesykdomTyskland, Belgia, Spania
-
Assiut UniversityUkjentSystemisk lupus erythematosus